SCHEMBL1682667

SCHEMBL1682667

O=C(Cn1cnnn1)c1ccccc1Cl

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HMOX1 P09601 1/20 0.50
▸ ALPG P10696 1/20 0.49
▸ ALDH1A1 P00352 2/20 0.49
▸ MAPT P10636 2/20 0.49
▸ KMT2A Q03164 4/20 0.45
▸ MEN1 O00255 3/20 0.45
▸ HSD17B10 Q99714 2/20 0.45
▸ KDM4E B2RXH2 1/20 0.45
▸ POLB P06746 1/20 0.45
▸ ALOX12 P18054 1/20 0.45
▸ RECQL P46063 1/20 0.45
▸ HBB P68871 1/20 0.45
▸ RAB9A P51151 3/20 0.45
▸ SMN1; SMN2 Q16637 2/20 0.45
▸ ERCC5 P28715 1/20 0.44
▸ FEN1 P39748 1/20 0.44
▸ CXCR3 P49682 1/20 0.44
▸ HSP90AA1 P07900 1/20 0.43
▸ PAX8 Q06710 1/20 0.43
▸ TP53 P04637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30817843 1.00 HMOX1 (0.50) HMOX1ALPGALDH1A1MAPTKMT2A
SCHEMBL6556662 0.84 MAPK1 (0.53) ALPGALDH1A1MAPTKMT2AMEN1
SCHEMBL7792067 0.78 ALPG (0.61) HMOX1ALPGALDH1A1MAPTKMT2A
SCHEMBL9714015 0.76 LMNA (0.49) ALDH1A1MAPTKMT2AMEN1HSD17B10
SCHEMBL21821206 0.73 PLAU (0.54) ALDH1A1KMT2AMEN1HSD17B10KDM4E
SCHEMBL30356468 0.73 POLB (0.58) ALDH1A1MAPTKMT2AMEN1KDM4E
SCHEMBL1682664 0.73 POLB (0.58) ALDH1A1MAPTKMT2AMEN1KDM4E
SCHEMBL30093208 0.71 KCNH2 (0.51) HMOX1ALPGALDH1A1HSD17B10POLB
SCHEMBL29669830 0.70 CA12 (0.56) ALPGKDM4E
SCHEMBL10878611 0.70 CA12 (0.56) ALPGKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117736157-A Preparation method of tetrazole-substituted acetophenone compound 江苏恩华药业股份有限公司 2024-03-22 — — CN disclosed
US-9434970-B2 Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester SK BIOPHARMACEUTICALS CO., LTD. (KR) 2016-09-06 — — US disclosed
US-20150252398-A1 METHOD FOR PREPARATION OF CARBAMIC ACID (R)-1-ARYL-2-TETRAZOLYL-ETHYL ESTER SK BIOPHARMACEUTICALS CO LTD (KR) 2015-09-10 — — US disclosed
US-9068207-B2 Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester SK BIOPHARMACEUTICALS CO. LTD. (KR) 2015-06-30 — — US disclosed
EP-2445890-B1 METHOD FOR PREPARATION OF CARBAMIC ACID (R)-1-ARYL-2-TETRAZOLYL-ETHYL ESTER SK BIOPHARMACEUTICALS CO LTD (KR) 2015-05-06 — — EP disclosed
EP-2488505-B1 METHOD FOR PREPARATION OF CARBAMIC ACID (R)-1-ARYL-2-TETRAZOLYL-ETHYL ESTER SK BIOPHARMACEUTICALS CO LTD (KR) 2015-02-25 — — EP disclosed
US-20140073018-A1 Method for Preparation of Carbamic Acid (R)-1-Aryl-2 Tetrazolyl-Ethyl Ester SK BIOPHARMACEUTICALS CO. LTD. (KR) 2014-03-13 — — US disclosed
US-8501436-B2 Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester SK BIOPHARMACEUTICALS CO. LTD. (KR) 2013-08-06 — — US disclosed
US-8404461-B2 Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester SK Biopharmaceutical Co. Ltd. (KR) 2013-03-26 — — US disclosed
EP-2488505-A2 METHOD FOR PREPARATION OF CARBAMIC ACID (R)-1-ARYL-2-TETRAZOLYL-ETHYL ESTER SK Biopharmaceuticals Co., Ltd. (KR) 2012-08-22 — — EP disclosed
EP-2445890-A1 METHOD FOR PREPARATION OF CARBAMIC ACID (R)-1-ARYL-2-TETRAZOLYL-ETHYL ESTER SK Biopharmaceuticals Co., Ltd. (KR) 2012-05-02 — — EP disclosed
US-20110111467-A1 Method for Preparation of Carbamic Acid (R)-1-Aryl-2-Tetrazolyl-Ethyl Ester SK BIOPHARMACEUTICALS CO. LTD. (KR) 2011-05-12 — — US disclosed
WO-2011046380-A2 METHOD FOR PREPARATION OF CARBAMIC ACID (R)-1-ARYL-2-TETRAZOLYL-ETHYL ESTER SK HOLDINGS CO.,LTD. (KR) 2011-04-21 — — WO disclosed
WO-2010150946-A1 METHOD FOR PREPARATION OF CARBAMIC ACID (R)-1-ARYL-2-TETRAZOLYL-ETHYL ESTER SK HOLDINGS CO., LTD. (KR) 2010-12-29 — — WO disclosed
US-20100323410-A1 METHOD FOR PREPARATION OF CARBAMIC ACID (R)-1-ARYL-2-TETRAZOLYL-ETHYL ESTER SK BIOPHARMACEUTICALS CO. LTD. (KR) 2010-12-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110111467-A1 Method for Preparation of Carbamic Acid (R)-1-Aryl-2-Tetrazolyl-Ethyl Ester CES1, ADH1A, ADH1C HMOX1 2984/4885ALPG 1722/4885ALDH1A1 46/4885
US-20100323410-A1 METHOD FOR PREPARATION OF CARBAMIC ACID (R)-1-ARYL-2-TETRAZOLYL-ETHYL ESTER CPS1, ADH1A, KHK HMOX1 3993/4885ALPG 2675/4885ALDH1A1 161/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback